<DOC>
	<DOCNO>NCT01045798</DOCNO>
	<brief_summary>This pilot feasibility study investigate antifungal therapy caspofungin patient high-risk develop invasive candidiasis critical care set .</brief_summary>
	<brief_title>Pilot Feasibility Study With Patients Who Are High Risk For Developing Invasive Candidiasis Critical Care Setting ( MK-0991-067 )</brief_title>
	<detailed_description>Hypothesis : In high-risk non-neutropenic participant ICU , proportion participant discontinue study therapy order empirically treat antifungal therapy suspect candidiasis outside context protocol le 20 % ( i.e. , upper bound 95 % confidence interval observe proportion le 20 % ) .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Hospitalization minimum 3 day ICU expectation stay ICU least another 48 hour Meets follow highrisk criterion : Requires mechanical ventilation time study entry ; central venous catheter place time study entry ; receive broad spectrum antibiotic time study entry ; AND meet least one follow criterion : Required parenteral nutrition current ICU admission ; require renal dialysis current ICU admission ; major surgery within 7 day current ICU admission ; diagnose pancreatitis within 7 day current ICU admission ; require systemic steroid immunosuppressive agent within 7 day current ICU admission Meets least one follow criterion suspect infection time study entry within 24 hour study entry : Temperature ≥38° C ≤36° C ( oral equivalent ) ; hypotension ( systolic blood pressure &lt; 90 mm Hg ) significant drop blood pressure ( 40 mm Hg ) participant 's normal baseline ; elevate white blood cell count ≥12,000/mm^3 Candida grow least one nonsterile culture site collect current ICU admission Female childbearing potential negative serum urine pregnancy test enrollment Females pregnant breast feed History allergy , hypersensitivity , serious reaction caspofungin another member echinocandin class ( e.g. , micafungin , anidulafungin ) Neutropenia expect develop neutropenia study therapy Diagnosis acquire immune deficiency syndrome ( AIDS ) , aplastic anemia , chronic granulomatous disease Diagnosis moderate severe hepatic insufficiency Patient expect survive least 24 hour Received systemic ( IV oral ) antifungal therapy within 10 day study entry Active diagnosis proven probable invasive fungal infection ( IFI ) Currently receive investigational agent within 10 day study entry Any condition concomitant illness might confuse study result pose additional risk administer study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Candidiasis</keyword>
	<keyword>Invasive Candidiasis</keyword>
	<keyword>Fungal Infection</keyword>
	<keyword>Empirical Therapy</keyword>
</DOC>